menu
    • menu
    [{"orgOrder":0,"company":"LaunXP Biomedical","sponsor":"Apollomics Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Vebreltinib","moa":"||tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Approved FDF","graph3":"LaunXP Biomedical","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"LaunXP Biomedical \/ LaunXP Biomedical","highestDevelopmentStatusID":"15","companyTruncated":"LaunXP Biomedical \/ LaunXP Biomedical"},{"orgOrder":0,"company":"LaunXP Biomedical","sponsor":"Efficient Pharma Management","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LXP1788","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"LaunXP Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LaunXP Biomedical \/ Efficient Pharma Management","highestDevelopmentStatusID":"6","companyTruncated":"LaunXP Biomedical \/ Efficient Pharma Management"}]

    Find Clinical Drug Pipeline Developments & Deals by LaunXP Biomedical

    Menu

    LaunXP Biomedical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LaunXP Biomedical

                            Taiwan arrow
                            CTAD25
                            Not Confirmed

                            LaunXP Biomedical

                            Taiwan arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vebreltinib,Osimertinib Mesylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Apollomics Inc

                            Deal Size : $60.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

                            Details : under the agreement, LaunXP receives exclusive development and commercialization rights for APL-101 (vebreltinib) in combination with an EGFR inhibitor for the treatment of non-small cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $10.0 million

                            March 31, 2025

                            Lead Product(s) : Vebreltinib,Osimertinib Mesylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Apollomics Inc

                            Deal Size : $60.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LaunXP Biomedical

                            Taiwan arrow
                            CTAD25
                            Not Confirmed

                            LaunXP Biomedical

                            Taiwan arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LXP1788

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Efficient Pharma Management

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.

                            Details : LXP1788 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 19, 2025

                            Lead Product(s) : LXP1788

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Efficient Pharma Management

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth